Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.


This research study is led by Dr. John McCann.

Contact: Dawn DeMarinis, 413-794-4362

Participation details:

December 13, 2013
Cancer, Cancer - Melanoma
  • D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
  • Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
Unresectable Stage III or Stage IV Melanoma; untreated or one previous treatment.
Interventional (Clinical Trial), Randomized